Loading...
XSHE
301207
, Last price  
Name

Hualan Biological Vaccine Inc

Chart & performance

D1W1MN
XSHE:301207 chart
P/E
—
P/S
—
EPS
0.31
Vol. 1Y
—
Shs. 5Y
1.96%
Rev. 5Y
-8.12%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.20b
+6.23%
284,911,400802,738,2001,048,988,2002,426,328,9451,829,813,8851,829,813,8851,825,640,9651,825,640,9652,410,428,4571,127,812,3231,198,101,824
Net income
183m
-10.99%
-76,881,600270,147,800375,297,700924,909,132620,972,414620,972,419519,634,804519,634,808859,968,606205,515,314182,919,690
CFO
500m
+6.91%
22,171,56494,456,132275,040,980693,711,957569,328,674288,662,214888,024,961468,041,442500,400,728
Dividend
Jun 15, 20260.8 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hualan Biological Bacterin Inc. is a Chinese pharmaceutical company focused on the entire vaccine lifecycle, from research and development to manufacturing and sales within China. The company's product line features a diverse range of immunizations, including various influenza virus vaccines (such as split, quadrivalent, and H1N1 strains), recombinant hepatitis B vaccines, and meningococcal polysaccharide vaccines (including ACYW135 and Group A & C types). They also develop genetically engineered vaccines for human use. Established in 2005, Hualan Biological Bacterin Inc. is headquartered in Xinxiang, China, and previously operated as a subsidiary of Hualan Biological Engineering Inc.
IPO date
Feb 18, 2022
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT